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Abstract
OBJECTIVES: The treatment of massive pulmonary embolism (PE) is a matter of debate. We present our institutional experience of
patients suffering from massive PE with the aim of comparing the early results, the outcome and quality of life (QoL) between patients
primarily assigned to either pulmonary surgical embolectomy (SE) or thrombolytic therapy (TL). A subgroup of patients (TS) with failed
responses to TL requiring SE was separately analysed.
METHODS: All consecutive patients (January 2001–December 2007) with computed tomography (CT)-scan-conﬁrmed massive bilateral
central or paracentral PE were reviewed. All clinical data were retrieved from our patients’ registry and completed by the evaluation of
the CT-scan-derived right ventricle/left ventricle ratio (RV/LV ratio). Follow-up focused on clinical outcome and QoL was obtained.
RESULTS: Eighty patients were analysed including 28 SE (35%) and 52 TL (65%), of whom 11 (21%) required TS. Demographics and
preoperative characteristics were similar between SE and TL. Analysis of the RV/LV ratio revealed a ratio of 1.66 for SE and 1.44 for TL.
The early mortality rate was not signiﬁcantly different between the two groups (SE: 3.6% versus TL: 13.5%), whereas early mortality was
27% in those patients treated initially with thrombolysis and subsequently requiring SE (TS-group). Severe bleeding complications were
lower in the SE-group (3.6% versus 26.5% P = 0.013). Intracerebral bleeding rates and neurological events were not statistically different.
After a mean follow-up of 63 ± 21 months, the mortality rate was 17.9% in the SE-group and 23.1% in the TL-group.
CONCLUSIONS: SE is an excellent treatment option in massive PE with comparable early mortality rates and signiﬁcantly less bleeding
complications than TL. Patients having surgery after inefﬁcient thrombolysis have the worst early outcome. The RV/LV CT-scan ratio
might serve as a predictor to differentiate patients, who could proﬁt from direct surgical intervention than thrombolytic treatment
attempts. Further studies are required to conﬁrm these results.
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INTRODUCTION
Patients presenting with acute massive pulmonary embolism (PE)
are at high risk of circulatory collapse, medical and mechanical
reanimation and late pulmonary hypertension. Their manage-
ment is challenging and still a matter of debate. Although recent
studies have repeatedly demonstrated good to excellent results
following surgical embolectomy (SE), current guidelines recom-
mend thrombolytic therapy (TL) as the treatment of choice,
whereas surgical management is reserved for high-risk patients,
in whom thrombolysis is absolutely contraindicated or has
failed [1].
Unfortunately, there is no current study comparing the two
treatment modalities. We reviewed our institutional experience
with patients referred with acute massive PE, who underwent
either TL or SE treatment.
PATIENTS AND METHODS
All consecutive institutional patients with acute massive central
or bilateral paracentral PE who underwent treatment between
January 2001 and December 2007 were retrospectively analysed.
The inclusion criteria were: acute massive PE deﬁned in com-
puted tomography (CT)-scan as central unilateral or bilateral or
paracentral bilateral embolism. Massive PE was deﬁned by >50%
occlusion of pulmonary vasculature or occlusion of two or
more lobar arteries or clinically as circulatory shock or
moderate-to-severe right ventricular dysfunction (RVD) detected
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by echocardiography [2]. Submassive PE was deﬁned as a
haemodynamically stable condition with RVD, or with one or
more of the following criteria present: cardiogenic shock
(deﬁned as systolic blood pressure <90 mmHg) associated with
clinical signs of organ hypoperfusion and hypoxia, syncope, and
pulmonary hypertension (>60 mmHg systolic pressure) or RVD.
Patients older than 80 years and those with a life expectancy
<6 months were excluded.
Two groups were deﬁned: patients who underwent TL and
patients who underwent SE. Patients who had undergone initial
TL followed by surgery (TS) were analysed in a separate group.
Clinical characteristics are summarized in Table 1. The revised
Geneva score was calculated according to Klol et al.[3] and a
high probability of PE was assigned when the score was superior
or equal to three. In addition, right/left ventricle (RV/LV) ratio
was calculated by measuring the RV/LV diameter at the level of
the posterior papillary muscle in the CT-scan, as described previ-
ously by Lu et al. [4].
All in-hospital data were assessed and the follow-up focused
on clinical statics and adverse events. In addition, the assessment
of quality of life (QoL) was carried out by Short-Form-36 (SF-36)
questionnaires.
Thrombolytic therapy
Indication for TL was based on the current guidelines of
the American College of Chest Physicians and consisted
of Alteplase started with a bolus of 15 mg followed by 85 mg
infusion over 2 h.
Unsuccessful TL was deﬁned as both persistent clinical in-
stability (refractory cardiogenic shock, systemic arterial hypoten-
sion <90 mmHg, severe hypoxemia with oxymetry <90% or a
PaO2 without O2 therapy of <55 mmHg or tachycardia >90 bpm)
and residual RVD demonstrated at echocardiography during the
ﬁrst 36 h after the start of lysis.
Surgical therapy
Indication for SE was a central or paracentral bilateral massive PE
with additional clinical criteria such as cardiopulmonary resusci-
tation, dysfunction of the RV, intracardiac thrombus or contra-
indication for TL.
SE was performed through a median sternotomy using mild
hypothermic or normothermic cardiopulmonary bypass (CPB).
The main pulmonary artery was opened with a longitudinal inci-
sion, which was extended into the right or left pulmonary artery
branches. The thrombotic material was extracted using a special
forceps and by assisting suction. To ensure complete clot removal,
the left and right pulmonary artery branches were inspected up
to the segmental arteries using a ﬂexible surgical angioscope. The
right atrium and ventricle were explored routinely, all clot material
was carefully removed and a patent foramen ovale was closed if
present. The pulmonary arteriotomy was closed with a 4/
0-running suture, and the patients weaned from CPB.
Post-intervention therapy
SE patients received intravenous unfractioned heparin immedi-
ately after surgery, which was maintained at a dosage of 1000
UI/h and later adapted to achieve an activated partial
thromboplastine-time ratio of at least twice the control value.
All patients received oral anticoagulation therapy, starting on
the second day and continued for at least 1 year with an
International Normalized Ratio range between 2 and 3.
Deﬁnition of clinical endpoints
The clinical endpoints during hospitalization were: mortality,
recurrent PE, neurological complications (ischaemic or haemor-
rhagic stroke conﬁrmed by CT-scan) and bleeding complications
requiring blood transfusion, surgical revision or discontinuation
of TL.
Endpoints at the follow-up were: mortality, recurrent PE and
QoL as assessed by SF-36.
Follow-up
All patients were contacted and a disease-speciﬁc questionnaire
—focusing on the areas of current medication, especially anticoa-
gulation therapy, thrombembolic or haemorrhagic complica-
tions, recurrent embolic events, re-hospitalization, assessment of
NYHA class- was obtained, as well as the German version of the
SF-36 Health Survey Questionnaire [5]. Details of this validated
questionnaire have been published previously. Brieﬂy, SF-36
consists of 36 short questions reﬂecting QoL in eight different
areas: bodily pain (2 items); mental health (5); vitality (4);
social functioning (2); general health (5); physical functioning








Age (year) 56.3 ± 2.7 56.5 ± 2 0.92
Weight (kg) 82.9 ± 3.7 79.8 ± 2.7 0.45




Heart rate 110 110 0.72
Deep venous thrombosis 39% 34% 0.1
Neoplasm 10.7% 16% 0.31
Immobilization 53.5% 78.8% 0.005
Post-PE 10.7% 13.4 1
Post-traumatic 7% 9.6% 1
Systolic PAP (mmHg) 72 53 0.01
Dyspnoea 14% 5.7% 0.23
Sat O2 86 85 0.45
NYHA ≥IV 46% 35.4 0.002
Cardiac insufficiency 82% 77% 0.77
Revised Geneva score ≥3 64% 52% 0.59
Shock index 1.1 ± 0.5 1.1 ± 0.5 0.86
Echocardiographic
RV dilatation 3.5% 10.8% 0.4
LV EF (%) 59.4 ± 7.5% 60.4 ± 11.1% 0.25
CT-scan
Central 21.5% 38% 0.14
Bilateral paracentral 78.5 59 0.13
R/L ventricular ratio 1.66 1.44 P = 0.04
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(10) and role functioning, both emotional (3) and physical (4).
Role functioning reﬂects the impact of emotional and physical
disability on work and regular activity (the individual’s normal
everyday role). Raw points were transformed, generating a score
for each dimension ranging from 0 to 100, with 100 reﬂecting
best functioning. Swedish normal population (n = 8930) scores
are used as a standard population for comparison.
Statistical analysis
Analyses were performed using SPSS Statistics 17.0 for Windows.
Patient characteristics are described using mean with standard
deviation, or absolute numbers with percentages as appropriate.
To minimize bias, continuous variables were generally assumed
non-parametric and compared using the Mann–Whitney U-test.
Proportions were compared using Fisher’s exact test, and cumu-
lative survival estimates using log-rank statistics. We performed
logistic regression modelling for prediction of 30-day mortality,
adjusting for the suspected confounding factors such as age and
shock index. We performed linear regression analyses with the
same set of independent variables to predict the two major
aspects of QoL: physical and psychological health. Results are
reported as hazard ratios for the logistic regression with 95%
conﬁdence intervals (CIs). The SF-36 questionnaire was analysed
in accordance with the SF-36 manual.
All tests used were two-sided, and differences were consid-
ered statistically signiﬁcant for P < 0.05.
RESULTS
Of the 125 indentiﬁed patients, 80 consecutive patients with a
complete clinical dataset were included, of whom 28 patients
(35%) underwent SE, 52 patients (65%) underwent TL, including
11 patients (21%) undergoing surgery after failed lysis (TS).
No signiﬁcant differences were found between the demogra-
phical and pre-interventional characteristics of the two groups
(Table 1). Signiﬁcant differences were seen in the preoperative
pulmonary artery pressure, which was higher in the SE-group
(72 ± 9 versus 52 ± 25 mmHg for TL-group; P = 0.01), and for the
CT-scan RV/LV ratio, 1.67 for SE patients versus 1.43 for TL
patients (P = 0.04). Interestingly, the analysis of the TS-group
revealed a ratio of 1.63 close to the surgical group, while TL
patients having an efﬁcient lysis alone showed a ratio of 1.39.
Results and complications are shown in Table 2. The early
mortality rate was not signiﬁcantly different between the two
groups, with 3.6% (n = 1) in the SE group and 13.5% (n = 7) in the
TL group, whereas early mortality was 27% (n = 3) in those
patients treated initially with thrombolysis and subsequently
requiring SE-(TS-group).
Bleeding complications were signiﬁcantly more frequent in
the TL-group (27 versus 3.6% in the SE-group, P = 0.01). One
patient suffered from intracerebral bleeding in the SE-group and
two patients (4.4%) in the TL-group. Overall neurological compli-
cations were found in 17.9% (n = 5) in the SE-group and in 20.4%
(n = 10) in the TL-group (P = 1.0).
The mean duration of the hospital stay was 14.0 ± 12.4 days
after surgery and 10.9 ± 10.6 days after lysis therapy. In the
TL-group, two patients underwent a second thrombolysis.
The follow-up was 95% complete with a mean of 63 ± 21
months, and the overall mortality was not signiﬁcantly different
between the two groups (17.9% SE-group versus 23.1%
TL-group). Figure 1 shows the Kaplan–Meier survival curve with
no difference between the groups for the 5-year survival prob-
ability (SE: 0.78; CI: 0.69–0.87; versus TL: 0.82; CI: 0.76–0.87).
QoL and adverse long-term events
A total of 82% of the SF-36 and disease-speciﬁc questionnaires
were returned and answered correctly. The results (shown in
Fig. 2) demonstrate a well-preserved QoL for the physical and
psychological components with no signiﬁcant difference
between the two groups.
Recurrent PE was not reported in any patient. No deterior-
ation of NYHA class was found. Figure 3 shows the trend for
mortality, neurological events and the QoL.
DISCUSSION
PE is a common clinical condition, with a reported incidence rate
of up to 2.3 per 10 000 [6]. In the majority of cases, acute PE can
be well treated with supplementary oxygen, anticoagulation and,
if necessary, intensive care management by intravenous ﬂuids or
vasopressin administration with careful attention to RV ﬁlling.
Table 2: Early and late outcomes
Characteristics Surgery Lyse P-value
Early
Mortality 3.6% 13.5% 0.25
(26.5% for TS) 0.02
Duration of hospitalization 14 ± 12 10.9 ± 10.6 0.08
Bleeding 3.6% 26.5% 0.01
Cerebral bleeding 3.6% 4.4% 1
Neurological event 17.9% 20.4% 1
At follow-up
Mortality 17.9% 23.1% 0.6
(36.4% for TS)
Re-PE 0% 0% 1
Figure 1: Kaplan–Meier survival.
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However, massive PE, especially if bilateral, is usually not well-
supported, and standard medical therapy is often insufﬁcient to
avoid clinical decompensation. Several studies have demonstrated
the ability of thrombolytic agents to dissolve pulmonary emboli,
thus improving pulmonary perfusion and RV function [7]. Based
on this data, current guidelines recommend treatment of more
severe cases, such as submassive and massive PE, with TL.
On the other hand, several clinical reports have shown that
surgical treatment of massive PE provides good to excellent
results. Nevertheless, current guidelines reserve SE to high-risk
patients only—patients in whom thrombolysis (TL) is absolutely
contraindicated or has failed. Direct comparing studies for the
two treatment modalities are missing.
As previously reported by us and others, the revealed early
mortality and complication rate after SE is low, and thus favourably
comparable to TL [8–13]. In contrast, in this study, we found a sig-
niﬁcantly higher mortality rate among patients who have under-
gone initially unsuccessful lysis, which had to be converted to SE.
In this subgroup of patients, the mortality rate was as high as 27%.
The rate of unsuccessful lysis and the outcome of such
patients in acute massive PE is not well documented in the lit-
erature. The rate varies between 5 and 10% and the mortality
rate has been reported up to 38%. Furthermore, it has been
shown that rescue SE may be offered to patients after a failed
lysis with a better outcome than a repetitive TL attempt [14].
Consequently, early indicators would be of critical value for
decision-making and primary treatment allocation.
An interesting and relatively easily accessible parameter was
previously suggested to be the CT-based RV/LV ratio, whereby a
ratio of >0.9 seemed to correlate with a worse outcome and a
5-fold increase of death within 30 days [15, 16].
Analysis of our data revealed a higher mean value of the RV/
LV ratio for the two groups, with a signiﬁcant higher value in the
surgical group. In the subgroup of patients after failed lysis, we
observed a similar RV/LV ratio as studied in the SE-group. Based
on this ﬁnding, we propose that a LV/RV ratio of more than 1.5
may be considered as a cut-off value for allocating patients to SE
instead of assigning to lysis therapy. Obviously, this has to be
conﬁrmed by further studies including a higher number of
patients.
The overall complication rate was found to be lower for
severe bleeding complications in the SE-group, but the rate of
intracerebral bleeding events was not different among the two
groups. Severe bleeding complications are well known after lysis
therapy and have been reported in up to 25% of the patients
with a rate of intracranial haemorrhage as high as 4% [9].
The long-term studied mortality is in accordance with the
results by others, and appears to be mostly due to the under-
lying disease. The assessment of QoL shows a well preserved
QoL in comparison with the normal population, without differ-
ences between the two treatment options.
In summary, this study reveals a low early mortality rate
among patients undergoing SE. A comparison with lysis shows
an even better early survival for surgery, however, this did not
reach statistical signiﬁcance and the low power of the study has
to be considered when interpreting this ﬁnding. In contrast,
patients who underwent SE after the failure of lysis clearly dem-
onstrate a critically high mortality rate. If conﬁrmed in additional
studies, the CT-derived RV/LV ratio could be a useful parameter
to identify candidates who might beneﬁt from direct surgical
therapy instead of thrombolysis. The limitation of surgical
therapy for massive PE in patients in whom thrombolysis is abso-
lutely contraindicated or has failed appears to be too restrictive.
Current guidelines should be adapted with respect to the excel-
lent clinical and functional results of SE. Multicentric studies and
national registries should be conducted to provide missing
data in order to improve patient allocation and treatment
algorithms.
Conﬂict of interest: none declared.
Figure 3: Plot representation shows trends in favour of surgery or lysis for major events such as mortality and neurological complications as well as for QoL. *The
values displayed are exp(coefﬁcient), exp(coefﬁcient − 1.96 SE), exp(coefﬁcient + 1.96 SE), respectively.
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APPENDIX. CONFERENCE DISCUSSION
Dr H. Jakob (Essen, Germany): I have problems in understanding that you
measured a systolic blood pressure of 72 in your surgical group. To my
knowledge, an untrained right ventricle is not capable of raising the pressure
that high. So is there perhaps a chronic component in those patients?
Dr Roost: That could well be true; we don’t know. But it’s absolutely right,
what you say, that it’s a very high pressure for an untrained right ventricle to
overcome.
Dr Jakob: And did you follow up the pulmonary artery pressures; did they
come down to normal values over time?
Dr Roost: They do come down. I don’t have the data here, but they do
come down. We have not measured them routinely in the patients. But we
have a smaller subset in a study which was published earlier on for surgical
patients only, which showed nicely how they did come down immediately.
But it is a problem if you end up with a patient in the OR and you ﬁnd out
that it’s mostly a chronic problem; you, as a surgeon, have a problem there,
so that’s absolutely important.
Dr Jakob: What about the consequence of your study? I think you demon-
strated nicely that this right ventricular/left ventricular ratio could perhaps be
a cutoff point for decision-making; are your internal medicine colleagues
accepting that in Berne?
Dr Roost: That’s exactly the problem, because these patients are initially
seen by the internist or the emergency medicine people. They ﬁrst call the
cardiologists who do the lytic therapy. Therefore the reason why we started
to analyse our results was actually because we wanted to be there and
involved in discussing the patients early on so that we can, perhaps, with that
ratio, identify patients who would really proﬁt from early surgery as opposed
to lytic therapy. It’s clear that in the great majority of patients you can avoid
surgery, which is ﬁne for them. But if you can save the few patients who
probably need to have surgery later on, then you can really do something
good.
So with that data, we wanted to address that in our hospital, which we
have actually done. You can see that the ratio was different between the
surgery and the thrombolytic therapy groups. I didn’t present it here, but in
the few patients, these 11 patients, who had to have surgery later on, they
had a ratio much closer to the surgery group, so we do think it’s actually an
important parameter.
Dr Jakob: And one last question, these were all in-house patients?
Dr Roost: Yes.
Dr Jakob: But what are your colleagues doing in the peripheral hospitals?
Do they contact you directly or do patients go to the internal medical depart-
ment prior to surgery?
Dr Roost: Yes. We are not contacted ﬁrst. And that’s the problem. We only
see the patients if the cardiologist or the people from emergency medicine
contact us.
Dr Jakob: But you are losing time.
Dr Roost: Exactly. So we hope that with this data we hopefully can change
that.
Dr T. Shah (Ahmedabad, India): I have two questions. What were the
reasons for the 17.9% late mortality? Secondly, do you have a choice
amongst the three thrombolytics that you enumerated? Is there anything
which gives better results and fewer complications versus the others?
Dr Roost: Honestly, I do not have the data about the causes of death in the
follow-up. You would have to contact Dr. Kadner, who actually gathered the
data. And regarding the three agents, usually we use alteplase. And actually,
that’s the cardiologist’s work, which agent is used, so I probably can’t answer
the question perfectly.
Dr S. Cebotari (Hannover, Germany): Do you have experience of using
ECMO in failed right ventricle in these patients before operation, after
operation?
Dr Roost: That’s what we would do. If you have a patient that you cannot
wean from bypass after removal of all the clots, what we would do is keep
him on ECMO hoping that the right ventricle does recover. And I think in
this group there was one patient we had to put on ECMO and who
recovered.
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